- ISIN DE000A0BL849
- Country Deutschland
Vita 34 AG
Vita 34 publishes preliminary figures on the course of business in 2023
|
Vita 34 AG / Key word(s): Preliminary Results/Forecast Vita 34 publishes preliminary figures on the course of business in 2023 Leipzig, 31 January 2024 – Vita 34 AG closed the year 2023, in view of a challenging environment, solidly from a purely operational perspective. However, a number of extraordinary charges caused the earnings development to fall short of expectations. Based on initial preliminary figures on business performance, Group revenue in 2023 amounted to EUR 76.8 million, which is in the communicated guidance range of EUR 75 to 82 million. Preliminary earnings before interest, taxes, depreciation and amortization (EBITDA) amounted to EUR 4.0 million, which is below the communicated guidance range of EUR 5.5 to 7.0 million. While the development of purely operating earnings was still generally in line with expectations, a number of extraordinary charges, which the company has already reported on in news publications, resulted in earnings falling short of the guidance corridor. These include mainly one-off charges for the downsizing of the Management Board, the charges for the capital increase, the consulting charges in connection with internal investigations at a subsidiary as well as in connection with the lawsuit against the licensor of the CAR-T technology and an unexpected increase in charges for the audit of 2023. The total extraordinary charges arising from the aforementioned items amounted to EUR 1.5 million. — End of inside information pursuant to Art. 17 MAR — End of Inside Information Information and Explanation of the Issuer to this announcement: According to current planning, the company will publish the complete Annual Report 2023 on 30 April 2024. Contact: Company profile Vita 34 was founded in Leipzig in 1997 and is today by far the leading cell bank in Europe and the third largest worldwide. As Europe’s first private cord blood bank and a pioneer in cell banking, the company has since offered collection logistics, processing and storage of stem cells from umbilical cord blood, umbilical cord tissue and other postnatal tissues as a full-service cryopreservation provider. Due to the expansion of its business model following the merger with PBKM, the company plans to invest in cell and gene therapies and CDMO. The body’s own cells are a valuable starting material for medical cell therapy and are kept alive in the vapor of liquid nitrogen. Customers from around 50 countries have already ensured the health of their families with more than 930,000 units of stored biological material at Vita 34.
31-Jan-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | Vita 34 AG |
| Deutscher Platz 5a | |
| 04103 Leipzig | |
| Germany | |
| Phone: | +49(0341)48792-40 |
| Fax: | +49(0341)48792-39 |
| E-mail: | ir@vita34.de |
| Internet: | www.vita34.de |
| ISIN: | DE000A0BL849 |
| WKN: | A0BL84 |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1827449 |
| End of Announcement | EQS News Service |